🇺🇸 FDA
Patent

US 8226980

Orally disintegrating solid dosage forms comprising progestin and methods of making and using thereof

granted A61KA61K31/56A61K9/0056

Quick answer

US patent 8226980 (Orally disintegrating solid dosage forms comprising progestin and methods of making and using thereof) held by TEVA WOMEN'S HEALTH, INC. expires Mon Jul 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA WOMEN'S HEALTH, INC.
Grant date
Tue Jul 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/56, A61K9/0056, A61K9/2018, A61K9/2054